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Abstract
In this report, we describe a case of atypical neuroleptic malignant syndrome (NMS) presenting with an isolated lesion in
the splenium of the corpus callosum (ILSCC). There is a paucity of information regarding this topic within the literature and
only 7 previous case reports have been published at the time of writing. To our knowledge, this case report is also the first
to describe an atypical NMS variant in the context of an ILSCC. In this report, we describe the important considerations
in formulating differential diagnosis for ILSCC and are the first report to propose a possible pathophysiological mechanism
relating ILSCC with NMS.
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Introduction
Isolated lesions in the splenium of the corpus callosum
(ILSCC) are an uncommon radiographic entity with an estimated prevalence between 0.6% and 3.0%.1,2 ILSCCs are
most commonly associated with a clinical presentation of
delirium and have a broad differential diagnosis.2 With
regard to neuroleptic malignant syndrome (NMS), recent literature has suggested a disease spectrum model with emphasis on identifying prodromal and atypical NMS variants in
order to improve disease outcomes.3-5 Considering the estimated incidence of NMS is between 0.01% and 0.02%, the
co-occurrence of ILSCC and NMS is either exceedingly rare
or an underrecognized clinical phenomenon.6 At the time of
writing, only 7 publications exist documenting ILSCC in the
context of NMS, the first of which was published in 2009.7-13
In this report, we are the first to describe a case of atypical
NMS presenting with an ILSCC. We are also the first to publish a case report to postulate a possible pathophysiological
relationship between the development of ILSCC and NMS.

Case Presentation
The patient was a 45-year-old male with a past medical history of intermittent asthma, hypertension, and type 2 diabetes mellitus who presented to the emergency department
(ED) via ambulance status post fall in the context of phencyclidine (PCP) intoxication. Initially in the ED the patient was

urinating on the floor, attempting to fight staff members, and
uncooperative with examination. Intravenous haloperidol 5
mg and midazolam 4 mg were administered for agitation,
after which the patient was able to tolerate medical evaluation and management. Additional history was limited at this
time given the patient’s intoxicated state. The patient was
unable to participate in a formal review of systems given his
altered mental status (AMS). Initial vital signs were blood
pressure 146/83 mm Hg, pulse 104 beats per minute, temperature 98.4 °F, respiratory rate 18 breath per minute, and
oxygen saturation 98%. Physical examination was grossly
normal aside from a 3 cm stellate forehead laceration. Apart
from a leukocytosis of 15 K/mm3, complete blood count, and
comprehensive metabolic panel were within normal limits.
Pertinent normal laboratory test results included a sodium of
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Figure 1. Images A, C, and E represent DWI, FLAIR, and ADC results, respectively, on initial imaging. Images B, D, and F represent
DWI, FLAIR, and ADC results, respectively, 11 days after initial imaging. FLAIR, fluid-attenuated inversion recovery; DWI, diffusionweighted imaging; ADC, apparent diffusion coefficient.

140 mmol/L, blood urea nitrogen of 15, and a creatinine of
0.87 mg/dL. Urine drug screen was positive for benzodiazepines and PCP. Urinalysis was positive for only bacteria and
nitrites along with 6 to 9 epithelial cells per high-power field
suggesting possible contamination. Urine cultures were not
obtained. Computerized tomography (CT) imaging demonstrated left zygomaticomaxillary complex fractures without
acute intracranial pathology. CT imaging of the patient’s cervical spine did not demonstrate any acute pathology. While
in the ED, the patient’s forehead laceration was sutured. The
patient was admitted to an inpatient medicine unit for further
management of his AMS and facial fracture.
On admission, the patient was somnolent, oriented only to
self, and unable to engage with the admission assessment. An
extensive AMS workup was completed, which included
ammonia, vitamin B12 and folate levels, thyroid-stimulating
hormone, blood cultures, C-reactive protein, repeat comprehensive metabolic panel/complete blood count, syphilis
screen, and repeat head CT. Aside from a mildly elevated
C-reactive protein of 2.6 mg/dL and leukocytosis of 14.2 K/
mm3 the remainder of the patient’s laboratory test results was
within normal limits. Specific laboratory tests of interest

pertinent to a delirium workup returned within normal limits
as follows: ammonia 15 µmol/L, thyroid-stimulating hormone 0.4, vitamin B12 576 pg/mL, and folate 22.9 ng/mL.
The differential diagnosis for the patient’s AMS remained
wide, so he was placed on the Clinical Institute Withdrawal
Assessment for Alcohol protocol and started on intravenous
thiamine as a history of alcohol use could not be ruled out.
The patient was also given a 3-day course of intravenous ceftriaxone considering equivocal urinalysis findings. Plastic
surgery was consulted and recommended nonemergent elective repair of the facial fractures, but treatment was deferred
as the patient remained altered and could not consent to the
procedure.
Per family collateral, the patient worked part-time as a
mechanic, lived alone, performed all activities of daily living
independently, and did not have any history of neurologic or
psychiatric disease. Family was unable to provide any additional information regarding the patient’s substance use. The
patient did not receive any additional lorazepam per Clinical
Institute Withdrawal Assessment for Alcohol protocol or for
vital sign abnormalities consistent with alcohol withdrawal.
Aside from his tachycardia on initial presentation in the ED,
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the patient did not demonstrate tachycardia after admission to
the inpatient medicine unit. On the third hospital day, the
patient’s AMS persisted, and neurology was consulted and
evaluated the patient for additional causes of encephalopathy.
On the consulting neurologist’s initial examination, the
patient remained lethargic, oriented only to self, unable to
follow complex commands, and hypophonic with increased
speech latency. No focal cranial nerve deficit was appreciated; however, the patient exhibited hypertonicity with significant oppositional paratonias in all 4 extremities along
with bilaterally upgoing plantar reflexes. Magnetic resonance imaging (MRI) and electroencephalography (EEG)
were ordered per neurology recommendations. EEG did not
demonstrate epileptiform activity or generalized slowing.
However, MRI revealed a restricted diffusion/focal hyperintensity within the splenium of the corpus callosum on diffusion-weighted imaging (DWI) and fluid-attenuated inversion
recovery (FLAIR) images, respectively. MRI findings on
FLAIR, DWI, and ADC (apparent diffusion coefficient) are
highlighted in Figure 1. In consideration of the patient’s
recent exposure to neuroleptics, persistent encephalopathy,
and significant oppositional paratonias, the possibility of an
atypical variant of NMS contributing to the patient’s delirium was likely. Despite the likelihood of atypical NMS, in
considering the wide differential diagnosis of callosal lesions
the probability of the MRI lesion representing a new infarct
remained. Therefore, the patient was placed on standing
aspirin 325 mg along with atorvastatin 40 mg daily. CT angiography of the head and neck was completed and was unremarkable. The patient was also started on standing
benztropine 1 mg twice daily for atypical NMS. Of note,
lorazepam was not used as there was concern for additional
central nervous system depression in an already somnolent
and delirious patient.
By the seventh hospital day, the patient became more
alert, had improved orientation, was able to complete 2 step
commands with prompting, and had reduced cogwheeling on
examination. Additionally, the patient’s leukocytosis had
down-trended to 13.2 K/mm3. The scheduled benztropine
was also discontinued. The patient did not require any physical restraints or tranquilizers for agitation after admission.
The patient’s MRI was repeated 11 days after initial imaging,
which redemonstrated the corpus callosum splenium hyperintensity on FLAIR imaging and without restricted diffusion
on DWI. The patient was instructed to repeat imaging as an
outpatient to confirm the diagnosis of subacute callosal
infarct versus transient splenial lesion of another etiology.
The patient was recommended to be discharged to a rehabilitation facility to further manage his physical deconditioning
and was subsequently lost to follow-up.

Discussion
At the time of writing, this is only the eighth documented case
demonstrating concurrent ILSCC and NMS pathology.7-13
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NMS has phenotypic heterogeneity and should be viewed on
a disease spectrum rather than as a discrete syndrome.3 Fever
and autonomic instability are usually late findings in NMS,
which can make identifying early presentations of NMS especially challenging.14 Consequently, a common disease variant
lacking core malignant features has been conceptualized in
the literature as atypical NMS.5 However, there is considerable uncertainty whether atypical NMS represents a distinct
pathology or a prodromal phase destined to evolve with
malignant features. Some authors have even proposed a
multi-staged disease model of NMS in order to better account
for atypical presentations.4 Of note NMS is a clinical diagnosis and specific laboratory or imaging results are not required
to confer a diagnosis.15 For instance, our patient’s EEG was
without epileptiform activity or generalized slowing, but positive EEG findings are not required to diagnose NMS or delirium. In fact, a recent review suggested EEG testing may have
a false positive and false negative rate as high as 20% when
evaluating delirium.16 Therefore, despite being afebrile during this hospitalization, the diagnosis of atypical NMS can
still be rendered in our patient considering significant oppositional paratonias and altered mental status in the context of
recent neuroleptic exposure. Given our patients atypical NMS
variant, an intensive care unit level of treatment including
dantrolene was not required, especially in the absence of
malignant features. Also, while benztropine is not a common
therapeutic in the armamentarium for NMS care, mechanistically it functions similarly to alternative treatments like
amantadine and bromocriptine. A core pathway within NMS
pathophysiology is a depletion of basal ganglia dopaminergic
neurotransmission secondary to neuroleptic exposure.17
Dopaminergic drugs like amantadine and bromocriptine can
be used to target this aberrant neurotransmission; however, in
addition to its anticholinergic properties benztropine can also
promote dopamine neurotransmission, making it a reasonable
therapeutic in cases of atypical NMS.18
There remains some diagnostic uncertainty regarding the
precise etiology of our patient’s ILSCC. A wide differential
diagnosis exists for splenial lesions, which we have outlined
in Table 1.19,20 For our patient, the differential included the
following: ischemic lesion, oncologic lesion, traumatic lesion,
transient splenial lesion secondary to NMS, and MarchiafavaBignami disease. With regard to ischemic etiologies, callosal
infarcts are rare and unlikely to be isolated, as in our patient,
due to a rich vascular supply emanating from both the anterior
and posterior circulations.21,22 Additionally, our patient had an
unremarkable CT angiogram of the head/neck, is young, did
not have a history of infarct associated drug use, and was
without a previous history of atrial fibrillation or stroke, making an infarct less likely. Similarly, the possibility of an oncologic cause is unlikely given our patient did not have any
systemic symptoms of cancer, did not have a family history,
did not have a chronic prodrome of symptoms, and did not
have imaging findings consistent with a space occupying
lesion. It is feasible that our patient’s lesion was traumatic in
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Table 1. Reported Etiologies of Splenial Lesions Adapted From Park et al19 and Uchino et al20.
Diagnostic category
Traumatic
Oncologic
Vascular
Toxic/metabolic
Degenerative/immune
Drug induced
Infectious

Specific etiologies
Diffuse axonal injury, hemorrhage
Lipoma, lymphoma, glioma, germinoma, metastasis
Infarction, hypoxic/ischemic encephalopathy, posterior reversible encephalopathy syndrome, hemolytic uremic
syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Hypoglycemic encephalopathy, carbon monoxide intoxication, leukodystrophy
Multiple sclerosis, acute disseminated encephalomyelitis, Marchiafava-Bignami disease, Wallerian degeneration
Metronidazole-induced encephalopathy, neuroleptic malignant syndrome, anti-epileptic withdrawal
Neonatal central nervous system viral infections, human immunodeficiency virus, tuberculosis, influenza

origin considering his head injury prior to arrival and the high
axonal density within the corpus callosum predisposing it to
shearing forces.19 However, axonal injury is rarely found in
spatial isolation and would likely have a diffuse distribution
given the severity of our patient’s injury as evident by the
extent of his facial fractures.23 The probability of MarchiafavaBignami disease is doubtful given our patient did not have a
history of alcohol abuse, had normal vitamin B12 and folate
levels, had unremarkable liver function tests, and received
prophylactic intravenous thiamine on admission.
Within previously published case reports documenting
ILSCC in the context of NMS, the MRI lesion was characterized as midline symmetric ovoid, which matches the distinct
morphology of our patient’s lesion.19 Prior reports have
shown a complete resolution of the MRI lesion within 2 to 12
weeks.7-13 In this case, imaging at 11 days showed a persistent lesion. Consequently, it remains possible that if reimaged later on, our patient’s lesion may have been found to be
transient as in the previously documented cases. Therefore,
the possibility of an NMS associated lesion seemed plausible
given our patients unique clinical picture without other compelling etiologies. Despite being first described over a decade
ago by Al-Edrus and colleagues,8 the pathophysiology of
ILSCC associated with NMS remains elusive, and none of
the existing case reports postulate an explanation.7,9-13
Further exploration of the mechanistic underpinnings of
ILSCC related to NMS may have utility in developing a
more thorough understanding NMS pathophysiology, which
might have diagnostic and treatment implications.
Despite the dearth of pathophysiologic postulates explaining the relationship between ILSCC and NMS within psychiatric publications, it is possible to synthesize a possible
mechanism from existing findings within the basic science
literature. Transient callosal cytotoxic edema has been extensively reviewed by Starkey and colleagues24 and defined as a
common etiology of ILSCC. They suggest a cytokine-mediated glutamate-induced N-methyl-D-aspartate receptor
(NMDAR) excitotoxic process is central to the pathophysiology of cytotoxic edema within the corpus callosum.24 With
regard to NMS, Zhuravliova and colleagues25 demonstrated
that haloperidol interactions with NMDAR resulted in glutamate-independent cytochrome-C-dependent cytotoxicity.

This is especially pertinent to ILSCC as there is a higher density of callosal Aquaporin-4 channels, relative to other brain
regions, which are involved in cytochrome-C mediated cytotoxic pathways leading to localized edema.26,27 Additionally,
PCP has been shown to cause upregulation of central
NMDARs, which may have theoretically predisposed our
patient to an NMS associated ILSCC.28 This proposed mechanism may be sufficient to explain the pathophysiology of
these localized lesions in the context of NMS; however,
additional case reports and confirmatory research are necessary. Additionally, it is unclear if other antipsychotics mentioned in the previous case reports (risperidone, olanzapine,
clozapine, and quetiapine) have similar contributions to the
disease mechanism as haloperidol.

Conclusion
We have presented the first published case of an ILSCC
in the context of atypical NMS, outlined the differential
diagnosis for this rare finding, and postulated a neurobiological mechanism of disease. Given the widespread
use of neuroleptics and availability of MRI, it is likely
there are identified but unreported occurrences of these
lesions. Conversely, a greater number of patients presenting with a NMS-associated ILSCC without imaging
unbeknown to their clinicians is also possible. Regardless,
discussions of ILSCC and NMS expand the intellectual
scaffold for a richer understanding of antipsychotics,
NMS, clinical neuroscience, and potentially medical
decision making.
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